Lipigon Pharmaceuticals AB (publ) (LPGO.ST)
SEK 0.18
(4.24%)
SEK 0.18
(4.24%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.15 Million SEK | -25.73% |
| 2022 | 6.94 Million SEK | 7.41% |
| 2021 | 6.46 Million SEK | 186.23% |
| 2020 | 2.25 Million SEK | 117.0% |
| 2019 | 1.04 Million SEK | -2.44% |
| 2018 | 1.06 Million SEK | -99.83% |
| 2017 | 619.84 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 4.35 Million SEK | -15.66% |
| 2024 Q2 | 5.06 Million SEK | 16.46% |
| 2023 Q1 | 7.73 Million SEK | 11.4% |
| 2023 Q3 | 4.14 Million SEK | -44.97% |
| 2023 FY | 5.15 Million SEK | -25.73% |
| 2023 Q4 | 5.15 Million SEK | 24.5% |
| 2023 Q2 | 7.52 Million SEK | -2.69% |
| 2022 Q3 | 3.76 Million SEK | -67.89% |
| 2022 Q1 | 5.08 Million SEK | -21.4% |
| 2022 FY | 6.94 Million SEK | 7.41% |
| 2022 Q4 | 6.94 Million SEK | 84.41% |
| 2022 Q2 | 11.73 Million SEK | 130.81% |
| 2021 Q1 | 2.61 Million SEK | 15.58% |
| 2021 FY | 6.46 Million SEK | 186.23% |
| 2021 Q4 | 6.46 Million SEK | 67.38% |
| 2021 Q3 | 3.86 Million SEK | -12.78% |
| 2021 Q2 | 4.42 Million SEK | 69.63% |
| 2020 FY | 2.25 Million SEK | 117.0% |
| 2020 Q4 | 2.25 Million SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2019 FY | 1.04 Million SEK | -2.44% |
| 2018 FY | 1.06 Million SEK | -99.83% |
| 2017 FY | 619.84 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| NextCell Pharma AB | 13.68 Million SEK | 62.32% |
| Biovica International AB (publ) | 34.76 Million SEK | 85.164% |
| Abliva AB (publ) | 16.78 Million SEK | 69.263% |
| Active Biotech AB (publ) | 13.4 Million SEK | 61.507% |
| Aptahem AB (publ) | 8.99 Million SEK | 42.675% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 95.161% |
| BioInvent International AB (publ) | 90.45 Million SEK | 94.298% |
| BioArctic AB (publ) | 139.5 Million SEK | 96.303% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 67.997% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.671% |
| Cantargia AB (publ) | 54.97 Million SEK | 90.617% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -34.393% |
| CombiGene AB (publ) | 4.15 Million SEK | -24.11% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 97.596% |
| Fluicell AB (publ) | 8.91 Million SEK | 42.142% |
| Genovis AB (publ.) | 98.04 Million SEK | 94.739% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.565% |
| Mendus AB (publ) | 51.22 Million SEK | 89.931% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 55.415% |
| LIDDS AB (publ) | 3.75 Million SEK | -37.327% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 80.687% |
| Saniona AB (publ) | 86.08 Million SEK | 94.008% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 55.794% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 85.094% |
| Xintela AB (publ) | 14.01 Million SEK | 63.197% |
| Amniotics AB (publ) | 10.54 Million SEK | 51.095% |
| Corline Biomedical AB | 6.78 Million SEK | 24.024% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 62.546% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 88.831% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 91.593% |
| Intervacc AB (publ) | 21.68 Million SEK | 76.208% |
| Kancera AB (publ) | 17.97 Million SEK | 71.309% |
| Lipum AB (publ) | 7.53 Million SEK | 31.573% |
| Nanologica AB (publ) | 79.32 Million SEK | 93.498% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 87.376% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 98.93% |
| AcouSort AB (publ) | 10.37 Million SEK | 50.299% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 92.747% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 61.3% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 95.84% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -118.652% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 92.821% |
| Simris Alg AB (publ) | 148.93 Million SEK | 96.537% |
| Ziccum AB (publ) | 6.38 Million SEK | 19.255% |
| SynAct Pharma AB | 51.83 Million SEK | 90.049% |
| OncoZenge AB (publ) | 1.69 Million SEK | -203.59% |
| Camurus AB (publ) | 414.81 Million SEK | 98.757% |
| 2cureX AB (publ) | 2.93 Million SEK | -75.741% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -16.539% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 73.085% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | 0.711% |
| I-Tech AB | 16.2 Million SEK | 68.17% |
| Cyxone AB (publ) | 4.69 Million SEK | -9.885% |
| Biosergen AB | 5.08 Million SEK | -1.436% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | 35.111% |
| Alzinova AB (publ) | 9.33 Million SEK | 44.722% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 97.16% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 72.11% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -187.514% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 59.526% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | 28.953% |